CN113317506A - 一种降尿酸固体饮料及其制备方法 - Google Patents
一种降尿酸固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN113317506A CN113317506A CN202110639029.4A CN202110639029A CN113317506A CN 113317506 A CN113317506 A CN 113317506A CN 202110639029 A CN202110639029 A CN 202110639029A CN 113317506 A CN113317506 A CN 113317506A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- solid beverage
- raw material
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 109
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 229940116269 uric acid Drugs 0.000 title claims abstract description 101
- 235000013361 beverage Nutrition 0.000 title claims abstract description 71
- 239000007787 solid Substances 0.000 title claims abstract description 71
- 230000001603 reducing effect Effects 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 119
- 238000000605 extraction Methods 0.000 claims abstract description 63
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 30
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 30
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 30
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 30
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 30
- 239000000661 sodium alginate Substances 0.000 claims abstract description 30
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 30
- 229960005480 sodium caprylate Drugs 0.000 claims abstract description 27
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims abstract description 27
- 240000000249 Morus alba Species 0.000 claims abstract description 18
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 18
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 18
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 18
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 18
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 18
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 18
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241001251949 Xanthium sibiricum Species 0.000 claims abstract description 15
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 10
- 239000003765 sweetening agent Substances 0.000 claims abstract description 10
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 210000002421 cell wall Anatomy 0.000 claims abstract description 9
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 5
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- 239000000463 material Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 37
- 239000008139 complexing agent Substances 0.000 claims description 28
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 16
- 238000002791 soaking Methods 0.000 claims description 16
- 241000245665 Taraxacum Species 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 11
- 239000005913 Maltodextrin Substances 0.000 claims description 11
- 229940035034 maltodextrin Drugs 0.000 claims description 11
- 229930189775 mogroside Natural products 0.000 claims description 11
- 239000004227 calcium gluconate Substances 0.000 claims description 10
- 235000013927 calcium gluconate Nutrition 0.000 claims description 10
- 229960004494 calcium gluconate Drugs 0.000 claims description 10
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims description 8
- GQGKWSAYNSDSDR-UHFFFAOYSA-N hexachloro-lambda6-sulfane Chemical compound ClS(Cl)(Cl)(Cl)(Cl)Cl GQGKWSAYNSDSDR-UHFFFAOYSA-N 0.000 claims description 8
- 239000001282 iso-butane Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 240000002262 Litsea cubeba Species 0.000 abstract description 5
- 235000012854 Litsea cubeba Nutrition 0.000 abstract description 5
- 240000001949 Taraxacum officinale Species 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 235000020510 functional beverage Nutrition 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 36
- 239000008280 blood Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 28
- 241001122767 Theaceae Species 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 240000005561 Musa balbisiana Species 0.000 description 13
- 241000219304 Portulacaceae Species 0.000 description 13
- 230000000857 drug effect Effects 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000032895 transmembrane transport Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 244000153955 Reynoutria sachalinensis Species 0.000 description 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940116732 celery seed extract Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
本发明公开了一种降尿酸固体饮料及其制备方法,属于功能饮料品制备技术领域。所述降尿酸固体饮料,包括以下原料:赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓、水、烟酰胺、维生素C、钙盐、甜味剂、8‑水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮、包埋剂。本发明采用真空冷冻干燥和低温纳米粉碎技术对赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓等原料进行干燥粉碎处理,可最大程度保留其有效成分,再采用超声波细胞破壁和亚临界提取技术使有效成分全部溶出,提高利用率,促进吸收,制成的固体饮料能有效降低动物的尿酸值。
Description
技术领域
本发明属于功能饮料制备技术领域,具体涉及一种降尿酸固体饮料及其制备方法。
背景技术
随着人们物质生活水平提高和生活方式的改变,高尿酸血症(HUA)的发病率呈逐年升高趋势。HUA最常见的临床表现为痛风,给患者身心健康及生存质量造成严重的影响。尽管HUA不属于致命性疾病,但能诱发如心肌梗死、冠心病、糖尿病、高脂血症、代谢综合征及慢性肾脏疾病等多种重大疾病。因此,HUA已成为严重影响人们日常生活,威胁人健康的一种代谢性疾病。
高尿酸血症在防治方面主要是药物为主,大多是在高尿酸血症转化为痛风之后的用药分为化学药物和中药治疗方案。化学药物方面:急性痛风发作治疗主要采用秋水仙碱和非水杨酸类NSAIDs,而慢性痛风目前使用的药物主要有四大类:以嘌呤代谢关键酶为靶点的减少尿酸合成药物;以肾小管尿酸运体为靶点的排尿酸药物;黄嘌呤氧化还原酶和肾小管尿酸转运体的双重抑制剂;促进尿酸转化排泄的尿酸酶。中药治疗痛风的复方有四妙散,单方药物有银杏叶、大黄、虎杖、赤芍等。
据报导,具有降尿酸作用的药食两用中草药主要有荷叶、绞股蓝、玉米须、茯苓、山药、菊花等,但这些中草药单独使用的效果不够理想。
中国专利申请文献“一种降尿酸肽固体饮料、制备方法及用途(专利申请号:201811599533.0)”公开了一种降尿酸肽固体饮料、制备方法及用途,涉及固体饮料技术领域,该固体饮料的组份为:麦芽糊精、大豆肽粉、芹菜籽提取物、茯苓粉、海洋鱼低聚肽、低聚异麦芽糖、菊粉、维生素C、碳酸镁、烟酸、乳酸亚铁、葡萄糖酸锌、维生素B1、维生素B2、维生素B6、叶酸。应用主料和辅料,主要以小分子肽、矿物质、微量元素、维生素等相互配合调节人体各系统功能,使五脏六腑功能正常,修复受损的细胞,提高免疫力,增强清热祛湿的功效,化痰清热,利湿软坚,清热通络、平衡阴阳,改善身体排泄功能,并抑制嘌呤在身体的吸收转化,促进嘌呤随尿液排出机体外部,对降尿酸和预防痛风有明显的作用,同时利于消除其他不适症状,但存在降尿酸效果较差的问题。
发明内容
本发明的目的是提供一种降尿酸固体饮料的制备方法,以解决现有技术生产的饮料存在降尿酸效果较差的问题。
为了解决以上技术问题,本发明采用以下技术方案:
一种降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤180-220份、车前草30-50份、蒲公英40-60份、马齿苋60-80份、桑叶20-30份、土茯苓25-40份、水600-1000份、烟酰胺1-2份、维生素C 0.8-1.2份、钙盐1.5-2.8份、甜味剂3-5份、8-水杨酰胺基辛酸钠0.4-0.6份、海藻酸钠0.2-0.3份、茶多酚0.1-0.2份、聚乙烯吡咯烷酮0.3-0.5份、包埋剂2-3份。
进一步地,所述的降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤204份、车前草42份、蒲公英50份、马齿苋68份、桑叶26份、土茯苓30份、水800份、烟酰胺1.4份、维生素C1份、钙盐2份、甜味剂4份、8-水杨酰胺基辛酸钠0.5份、海藻酸钠0.2份、茶多酚0.2份、聚乙烯吡咯烷酮0.4份、包埋剂2.5份。
进一步地,所述的降尿酸固体饮料,所述的钙盐为葡萄糖酸钙。
进一步地,所述的降尿酸固体饮料,所述的甜味剂为罗汉果甜苷。
进一步地,所述的降尿酸固体饮料,所述的包埋剂为麦芽糊精。
本发明还提供一种降尿酸固体饮料的制备方法,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥至混合后的原料的水分含量≤6%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡10-15min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比为6-10:1,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/3-1/2体积后加入包埋剂进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-25至-35℃,加热温度为30-35℃,真空度为100-150Pa,干燥至包埋物料的水分含量≤1%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、钙盐、甜味剂、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
进一步地,步骤S2中真空冷冻干燥的条件为:冷阱温度为-40至-60℃,加热温度为36-40℃,真空度为200-300Pa。
进一步地,步骤S3中干燥原料放入到超低温纳米碎机中粉碎至纳米级的条件:在震动粉碎工作频率为5000-7000次/min,振幅为0.6-0.7cm,温度为-20至-32℃。
进一步地,步骤S5中浸泡原料采用低温超声波细胞破壁机破壁处理的条件为:温度为2-6℃,超声波频率为35-40kHz,处理时间为6-8min。
进一步地,步骤S6中以液化的亚临界萃取复合剂对破壁原料进行有效成分提取的条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4-7:1-2:2-4组成,提取压力0.45-0.6MPa,提取时间为12-18min。
本发明具有以下有益效果:
(1)本发明经过创新后优化工艺,采用真空冷冻干燥和超低温纳米粉碎技术对赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓进行干燥粉碎处理,其中优选的真空冷冻干燥的条件为:冷阱温度为-40至-60℃,加热温度为36-40℃,真空度为200-300Pa,干燥至混合后的原料的水分含量≤6%;优选的超低温纳米粉碎条件为:在震动粉碎工作频率为5000-7000次/min,振幅为0.6-0.7cm,温度为-20至-32℃,粉碎至纳米级。采用超低温真空冷冻干燥和超高频、超低温纳米粉碎技术,能够最大程度保留降低尿酸的有效成分。
(2)本发明对浸泡原料采用低温超声波细胞破壁机破壁处理,优选的条件为:温度为2-6℃,超声波频率为35-40kHz,处理时间为6-8min。利用超声波的“空化”作用,以达到激化浸泡原料渗透、溶解、扩散活性,为亚临界提取降低尿酸的有效成分提供了良好条件。
(3)本发明采用亚临界提取技术对破壁原料进行降低尿酸的有效成分提取,优选的条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4-7:1-2:2-4组成,提取压力0.45-0.6MPa,提取时间为12-18min。其中筛选萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4-7:1-2:2-4组成,不但所选萃取剂环保、无污染,而且使降低尿酸的有效成分全部溶出,提高利用率,促进吸收,并且保留提取物的活性成分不破坏、不氧化。本发明筛选的萃取复合剂与单萃取剂相比,不仅可以提高降低尿酸的有效成分的提取率,而且缩短了提取时间。
(4)本发明筛选的甜味剂为罗汉果甜苷,有利于改善固体饮料的口感,有利于避免使用白糖等含糖物质,有利于降低固体饮料的热量。
(5)本发明以赤苍藤为主要原材料,可以大力发展赤苍藤的种植,开发资源,促进农户增收;本发明综合赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓多种药材有效成分的效果,明显比传统的单方药物银杏叶、大黄、虎杖、赤芍等降低尿酸效果好。
(6)本发明给药后治疗组的小鼠的血尿酸平均值均显著小于饲喂现有技术制得的固体饮料的小鼠的血尿酸平均值,至少小59.8μmol/L,说明本发明的固体饮料降尿酸效果明显优于现有技术制备的固体饮料降尿酸效果。
(7)本发明制备的固体饮料中8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮一起使用时产生了协同作用,协同降低了药效检验后的小鼠血尿酸平均值,这是因为:8-水杨酰胺基辛酸钠在低浓度下影响小鼠内膜,与其输送到小鼠胃部的降尿酸药物相互作用,促进降尿酸药物在小鼠肠道中跨膜转运,提高降尿酸药物的吸收率;海藻酸钠具有优良的表面活性作用,促进降尿酸药物在小鼠肠道跨膜转运过程中的表面活性,进而提高降尿酸药物的吸收率;聚乙烯吡咯烷酮能够与茶多酚形成络合物,进而可防降尿酸药物凝胶,使其充分分散被小鼠肠道吸收,进而也提高了降尿酸药物的吸收率。综上,在8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮相互配合下,协同降低了小鼠药效检验后的血尿酸平均值。
具体实施方式
为了更好地理解本发明,现采用以下实施例加以说明,以下实施例属于本发明的保护范围,但不限制本发明的保护范围。
以下实施例中,所述降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤180-220份、车前草30-50份、蒲公英40-60份、马齿苋60-80份、桑叶20-30份、土茯苓25-40份、水600-1000份、烟酰胺1-2份、维生素C 0.8-1.2份、葡萄糖酸钙1.5-2.8份、罗汉果甜苷3-5份、8-水杨酰胺基辛酸钠0.4-0.6份、海藻酸钠0.2-0.3份、茶多酚0.1-0.2份、聚乙烯吡咯烷酮0.3-0.5份、麦芽糊精2-3份;
所述降尿酸固体饮料的制备方法,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥,条件为:冷阱温度为-40至-60℃,加热温度为36-40℃,真空度为200-300Pa,干燥至混合后的原料的水分含量≤6%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中,在震动粉碎工作频率为5000-7000次/min,振幅为0.6-0.7cm,温度为-20至-32℃下粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡10-15min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料,条件为:温度为2-6℃,超声波频率为35-40kHz,处理时间为6-8min;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比为6-10:1,提取条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4-7:1-2:2-4组成,提取压力0.45-0.6MPa,提取时间为12-18min,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/3-1/2体积后加入麦芽糊精进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-25至-35℃,加热温度为30-35℃,真空度为100-150Pa,干燥至包埋物料的水分含量≤1%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、葡萄糖酸钙、罗汉果甜苷、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
下面通过更具体的实施例加以说明。
实施例1
一种降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤185份、车前草32份、蒲公英40份、马齿苋63份、桑叶20份、土茯苓26份、水600份、烟酰胺1份、维生素C 0.8份、葡萄糖酸钙1.7份、罗汉果甜苷3份、8-水杨酰胺基辛酸钠0.4份、海藻酸钠0.2份、茶多酚0.1份、聚乙烯吡咯烷酮0.3份、麦芽糊精2份;
所述降尿酸固体饮料的制备方法,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥,条件为:冷阱温度为-40℃,加热温度为37℃,真空度为200Pa,干燥至混合后的原料的水分含量为5.3%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中,在震动粉碎工作频率为5000次/min,振幅为0.6cm,温度为-20℃下粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡12min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料,条件为:温度为4℃,超声波频率为35kHz,处理时间为7min;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比为7:1,提取条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4:1:2组成,提取压力0.48MPa,提取时间为17min,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/3体积后加入麦芽糊精进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-25℃,加热温度为31℃,真空度为100Pa,干燥至包埋物料的水分含量为1%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、葡萄糖酸钙、罗汉果甜苷、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
实施例2
一种降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤204份、车前草42份、蒲公英50份、马齿苋68份、桑叶26份、土茯苓30份、水800份、烟酰胺1.4份、维生素C1份、葡萄糖酸钙2份、罗汉果甜苷4份、8-水杨酰胺基辛酸钠0.5份、海藻酸钠0.2份、茶多酚0.2份、聚乙烯吡咯烷酮0.4份、麦芽糊精2.5份;
所述降尿酸固体饮料的制备方法,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥,条件为:冷阱温度为-52℃,加热温度为38℃,真空度为300Pa,干燥至混合后的原料的水分含量为4%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中,在震动粉碎工作频率为7000次/min,振幅为0.7cm,温度为-25℃下粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡13min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料,条件为:温度为2℃,超声波频率为40kHz,处理时间为6min;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比为8:1,提取条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为5:2:3组成,提取压力0.56MPa,提取时间为15min,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/2体积后加入麦芽糊精进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-28℃,加热温度为32℃,真空度为150Pa,干燥至包埋物料的水分含量为0.8%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、葡萄糖酸钙、罗汉果甜苷、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
实施例3
一种降尿酸固体饮料,按重量份为单位,包括以下原料:赤苍藤218份、车前草47份、蒲公英59份、马齿苋80份、桑叶30份、土茯苓38份、水980份、烟酰胺2份、维生素C1.1份、葡萄糖酸钙2.6份、罗汉果甜苷5份、8-水杨酰胺基辛酸钠0.6份、海藻酸钠0.3份、茶多酚0.2份、聚乙烯吡咯烷酮0.5份、麦芽糊精3份;
所述降尿酸固体饮料的制备方法,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥,条件为:冷阱温度为-52℃,加热温度为38℃,真空度为260Pa,干燥至混合后的原料的水分含量为3.8%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中,在震动粉碎工作频率为6000次/min,振幅为0.6cm,温度为-28℃下粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡14min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料,条件为:温度为5℃,超声波频率为39kHz,处理时间为7min;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比10:1,提取条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为7:2:3组成,提取压力0.55MPa,提取时间为14min,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/2体积后加入麦芽糊精进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-34℃,加热温度为32℃,真空度为120Pa,干燥至包埋物料的水分含量为0.8%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、葡萄糖酸钙、罗汉果甜苷、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
对比例1
与实施例2的制备方法基本相同,不同之处在于制备固体饮料的原料中缺少8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮。
对比例2
与实施例2的制备方法基本相同,不同之处在于制备固体饮料的原料中缺少8-水杨酰胺基辛酸钠。
对比例3
与实施例2的制备方法基本相同,不同之处在于制备固体饮料的原料中缺少海藻酸钠。
对比例4
与实施例2的制备方法基本相同,不同之处在于制备固体饮料的原料中缺少茶多酚。
对比例5
与实施例2的制备方法基本相同,不同之处在于制备固体饮料的原料中缺少聚乙烯吡咯烷酮。
对比例6
采用中国专利申请文献“一种降尿酸肽固体饮料、制备方法及用途(专利申请号:201811599533.0)”中实施例1的方法制备固体饮料。
降尿酸效果实验
1.造模液:浓度为4mg/mL的腺嘌呤水溶液;浓度为1.2g/mL的酵母膏水溶液。
2.实验动物:昆明种小鼠54只,SPF级,雌雄各半,19.1-22.4g;54只昆明种小鼠进行适应性饲养一周时间,之后随机分为治疗组1-3、对照组1-6,每组6只;分组后测量各小鼠初始血尿酸值并纪录,统计每组小鼠初始血尿酸平均值。
3.建立动物模型:
54只昆明种小鼠分别采用造模液灌胃,每天灌胃两次,连续灌胃8天制备成高尿酸血症模型;每次灌胃时,先按100ml/kg腺嘌呤的量给予腺嘌呤水溶液,再按30ml/kg酵母膏的量给予酵母膏水溶液。
造模结束后采小鼠尾部末梢血2滴,使用一次性芯片和仪器迅速测定,对各组小鼠造模结束后的血尿酸值并纪录,统计每组小鼠造模结束后的血尿酸平均值。
4.给药方法及血尿酸值检验:
治疗组1-3和对照组1-6的小鼠按以下用药,每只小鼠每天按1g固体饮料饲喂。
治疗组1:实施例1的固体饮料;
治疗组2:实施例2的固体饮料;
治疗组3:实施例3的固体饮料;
对照组1:对比例1的固体饮料;
对照组2:对比例2的固体饮料;
对照组3:对比例3的固体饮料;
对照组4:对比例4的固体饮料;
对照组5:对比例5的固体饮料;
对照组6:对比例6的固体饮料。
每组小鼠连续饲喂固体饮料2天,2天后测定各组小鼠药效检验后的血尿酸值并纪录,统计每组小鼠药效检验后的血尿酸平均值,对比初始血尿酸平均值,建模后血尿酸平均值和药效检验后血尿酸平均值,结果如下表1。
表1小鼠各个时期血尿酸平均值对比
由表1可知:(1)各组造模后较造模前血尿酸平均值显著升高,且整体水平由造模前的150μmol/L以上升高到330μmol/L以上,该结果说明造模成功。
(2)由表1的数据可见,本发明的实施例2制备的固体饮料在3个实施例中降低血尿酸含量方面的效果最佳。
(3)治疗组1-3的小鼠饲喂实施例1-3制备的固体饮料后,2天后由造模后血尿酸平均值336.2-339.9μmol/L降低到209.6-215.5μmol/L,且每天小鼠饲喂固体饮料用量少,但使用效果极佳。
(4)给药后治疗组1-3的小鼠的血尿酸平均值均显著小于对比例6(现有技术)的小鼠的血尿酸平均值,至少小59.8μmol/L,说明本发明的固体饮料降尿酸效果明显优于现有技术制备的固体饮料降尿酸效果。
(5)由实施例2和对比例1-5的数据可见,制备本发明的固体饮料中缺少8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮,均对降尿酸效果产生影响,其中影响最大的为8-水杨酰胺基辛酸钠。同时由实施例2和对比例1-5的药效检验后血尿酸平均值数据,可以计算得出8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮一起使用时产生了协同作用,协同降低了药效检验后的小鼠血尿酸平均值。具体计算如下:
1)由实施例2和对比例1的药效检验后血尿酸平均值数据可以计算得出8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮一起使用时降低的血尿酸平均值的效果值=|209.6-268.4|=58.8(μmol/L)。
2)由实施例2和对比例2的药效检验后血尿酸平均值数据可以计算得出8-水杨酰胺基辛酸钠单独使用时降低的血尿酸平均值的效果值=|209.6-224.8|=15.2(μmol/L)。
3)由实施例2和对比例3的药效检验后血尿酸平均值数据可以计算得出海藻酸钠单独使用时降低的血尿酸平均值的效果值==|209.6-219.7|=10.1(μmol/L)。
4)由实施例2和对比例4的药效检验后血尿酸平均值数据可以计算得出茶多酚单独使用时降低的血尿酸平均值的效果值=|209.6-221.4|=11.8(μmol/L)。
5)由实施例2和对比例5的药效检验后血尿酸平均值数据可以计算得出聚乙烯吡咯烷酮单独使用时降低的血尿酸平均值的效果值=|209.6-218.6|=9.0(μmol/L)。
可以计算得出8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮分别单独使用时叠加降低的血尿酸平均值的效果值=15.2+10.1+11.8+9.0=46.1(μmol/L)。
综上,可以计算得出8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮一起使用时降低的血尿酸平均值的效果值比8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮分别单独使用时叠加降低的血尿酸平均值的效果值提高的百分数=(58.8-46.1)÷46.1×100%=27.5%>10%,由于27.5%大于10%,说明了通过计算可得出8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮一起使用时产生了协同作用,协同降低了药效检验后的血尿酸平均值,这是因为:8-水杨酰胺基辛酸钠在低浓度下影响小鼠内膜,与其输送到小鼠胃部的降尿酸药物相互作用,促进降尿酸药物在小鼠肠道中跨膜转运,提高降尿酸药物的吸收率;海藻酸钠具有优良的表面活性作用,促进降尿酸药物在小鼠肠道跨膜转运过程中的表面活性,进而提高降尿酸药物的吸收率;聚乙烯吡咯烷酮能够与茶多酚形成络合物,进而可防降尿酸药物凝胶,使其充分分散被小鼠肠道吸收,进而也提高了降尿酸药物的吸收率。综上,在8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮相互配合下,协同降低了小鼠药效检验后的血尿酸平均值。
以上内容不能认定本发明具体实施只局限于这些说明,对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思前提下,还可以做出若干简单推演或替换,都应当视为属于本发明由所提交的权利要求书确定的专利保护范围。
Claims (10)
1.一种降尿酸固体饮料,其特征在于,按重量份为单位,包括以下原料:赤苍藤180-220份、车前草30-50份、蒲公英40-60份、马齿苋60-80份、桑叶20-30份、土茯苓25-40份、水600-1000份、烟酰胺1-2份、维生素C 0.8-1.2份、钙盐1.5-2.8份、甜味剂3-5份、8-水杨酰胺基辛酸钠0.4-0.6份、海藻酸钠0.2-0.3份、茶多酚0.1-0.2份、聚乙烯吡咯烷酮0.3-0.5份、包埋剂2-3份。
2.根据权利要求1所述的降尿酸固体饮料,其特征在于,按重量份为单位,包括以下原料:赤苍藤204份、车前草42份、蒲公英50份、马齿苋68份、桑叶26份、土茯苓30份、水800份、烟酰胺1.4份、维生素C1份、钙盐2份、甜味剂4份、8-水杨酰胺基辛酸钠0.5份、海藻酸钠0.2份、茶多酚0.2份、聚乙烯吡咯烷酮0.4份、包埋剂2.5份。
3.根据权利要求1或2所述的降尿酸固体饮料,其特征在于,所述的钙盐为葡萄糖酸钙。
4.根据权利要求1或2所述的降尿酸固体饮料,其特征在于,所述的甜味剂为罗汉果甜苷。
5.根据权利要求1或2所述的降尿酸固体饮料,其特征在于,所述的包埋剂为麦芽糊精。
6.一种根据权利要求1-5任一项所述降尿酸固体饮料的制备方法,其特征在于,包括以下步骤:
S1:按重量份比例称取赤苍藤、车前草、蒲公英、马齿苋、桑叶、土茯苓,然后混合原料,获得混合后原料;
S2:将步骤S1混合后的原料进行真空冷冻干燥至混合后的原料的水分含量≤6%,制得干燥原料;
S3:将步骤S2制得的干燥原料放入到超低温纳米碎机中粉碎至纳米级,制得粉碎原料;
S4:取步骤S3制得的粉碎原料并向其加入水浸泡10-15min,制得浸泡原料;
S5:取步骤S4制得的浸泡原料采用低温超声波细胞破壁机破壁处理,制得破壁原料;
S6:以液化的亚临界萃取复合剂对取步骤S5制得的破壁原料进行有效成分提取,所述萃取复合剂、破壁原料的质量比为6-10:1,提取完成后分离出萃取复合剂,制得提取药液;
S7:将步骤S6制得的药液浓缩至1/3-1/2体积后加入包埋剂进行包埋,制得包埋物料;
S8:将步骤S7制得的包埋物料进行真空冷冻干燥,条件为:冷阱温度为-25至-35℃,加热温度为30-35℃,真空度为100-150Pa,干燥至包埋物料的水分含量≤1%,制得干粉;
S9:向步骤S8制得的干粉加入烟酰胺、维生素C、钙盐、甜味剂、8-水杨酰胺基辛酸钠、海藻酸钠、茶多酚、聚乙烯吡咯烷酮调配均匀,制得调配物料;
S10:将步骤S9制得的调配物料进行灭菌、包装,制得降尿酸固体饮料。
7.根据权利要求6所述降尿酸固体饮料的制备方法,其特征在于,步骤S2中真空冷冻干燥的条件为:冷阱温度为-40至-60℃,加热温度为36-40℃,真空度为200-300Pa。
8.根据权利要求6所述降尿酸固体饮料的制备方法,其特征在于,步骤S3中干燥原料放入到超低温纳米碎机中粉碎至纳米级的条件:在震动粉碎工作频率为5000-7000次/min,振幅为0.6-0.7cm,温度为-20至-32℃。
9.根据权利要求6所述降尿酸固体饮料的制备方法,其特征在于,步骤S5中浸泡原料采用低温超声波细胞破壁机破壁处理的条件为:温度为2-6℃,超声波频率为35-40kHz,处理时间为6-8min。
10.根据权利要求6所述降尿酸固体饮料的制备方法,其特征在于,步骤S6中以液化的亚临界萃取复合剂对破壁原料进行有效成分提取的条件为:萃取复合剂由六氯化硫、异丁烷、甲乙醚按重量比为4-7:1-2:2-4组成,提取压力0.45-0.6MPa,提取时间为12-18min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110639029.4A CN113317506A (zh) | 2021-06-08 | 2021-06-08 | 一种降尿酸固体饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110639029.4A CN113317506A (zh) | 2021-06-08 | 2021-06-08 | 一种降尿酸固体饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113317506A true CN113317506A (zh) | 2021-08-31 |
Family
ID=77420185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110639029.4A Pending CN113317506A (zh) | 2021-06-08 | 2021-06-08 | 一种降尿酸固体饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113317506A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100912A (zh) * | 2009-12-16 | 2011-06-22 | 上海蓝心医药科技有限公司 | 一种给药组合物及其制备和使用方法 |
CN107373450A (zh) * | 2017-07-25 | 2017-11-24 | 烟台东极生物科技有限公司 | 一种超微高钙深海骨原粉及其制备方法和应用 |
CN108558725A (zh) * | 2018-07-20 | 2018-09-21 | 四川理工学院 | 一种低温亚临界萃取雨生红球藻中虾青素的方法 |
CN110559403A (zh) * | 2019-09-29 | 2019-12-13 | 南京海峪生物科技有限公司 | 具有防治高尿酸血症的中药组合物及其制备方法与应用 |
CN110755389A (zh) * | 2019-11-05 | 2020-02-07 | 北京本草方源药业集团有限公司 | 一种复方低温真空干燥提取粉及其提取方法 |
-
2021
- 2021-06-08 CN CN202110639029.4A patent/CN113317506A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100912A (zh) * | 2009-12-16 | 2011-06-22 | 上海蓝心医药科技有限公司 | 一种给药组合物及其制备和使用方法 |
CN107373450A (zh) * | 2017-07-25 | 2017-11-24 | 烟台东极生物科技有限公司 | 一种超微高钙深海骨原粉及其制备方法和应用 |
CN108558725A (zh) * | 2018-07-20 | 2018-09-21 | 四川理工学院 | 一种低温亚临界萃取雨生红球藻中虾青素的方法 |
CN110559403A (zh) * | 2019-09-29 | 2019-12-13 | 南京海峪生物科技有限公司 | 具有防治高尿酸血症的中药组合物及其制备方法与应用 |
CN110755389A (zh) * | 2019-11-05 | 2020-02-07 | 北京本草方源药业集团有限公司 | 一种复方低温真空干燥提取粉及其提取方法 |
Non-Patent Citations (3)
Title |
---|
傅强主编: "《现代药物分离与分析技术》", 31 August 2011, 西安交通大学出版社 * |
吴正红等主编: "《药剂学》", 30 April 2020, 中国医药科技出版社 * |
黄元河等: "赤苍藤醇提物的急性毒性及对小鼠高尿酸血症的影响", 《中国民族民间医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101738912B1 (ko) | 비만억제 및 다이어트 조성물 | |
JP6345243B2 (ja) | 円武扇発酵物含有食品または飲料組成物 | |
CN107080250A (zh) | 一种辅助降血糖的组合物、饮料及其制备方法 | |
CN107149068A (zh) | 一种蜂蜜醒酒饮料及其制备方法 | |
CN105410346A (zh) | 提高养殖对虾存活率的中药制剂及其制备方法 | |
CN104522635A (zh) | 一种抗疲劳制剂及其制备方法 | |
CN108175024A (zh) | 一种向日葵花粉固体饮料及制备方法 | |
CN102657304B (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN104432063A (zh) | 一种缓解运动性疲劳的组合物及其制剂 | |
CN102389114B (zh) | 具有缓解体力疲劳功能的保健食品及其制备方法 | |
CN104739964B (zh) | 一种蜗牛解酒制剂及其制作方法 | |
CN113317506A (zh) | 一种降尿酸固体饮料及其制备方法 | |
CN105410940B (zh) | 一种包含黄原胶的保健食品 | |
CN104644734A (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
CN113303472A (zh) | 一种利用赤苍藤生产的功能饮料及其制备工艺 | |
CN109805235B (zh) | 一种辅助降四高的麦香复合多肽固体饮料、制备方法及用途 | |
CN106138900A (zh) | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 | |
CN106165897A (zh) | 通过酶解制备的猕猴桃营养粉及其应用 | |
CN105838538A (zh) | 一种黑茶金花保健酒配方及其制备方法 | |
CN110420320A (zh) | 一种清除痛风发病基础的中药组合物 | |
CN102657333B (zh) | 降压护心复合营养剂及其制备方法 | |
CN102485263A (zh) | 一种治疗小儿久咳的药物组合物及制备方法 | |
CN107788180A (zh) | 一种稳定降血压的保健养生茶及其制备方法 | |
CN108720013A (zh) | 一组由果糖和茶叶提取物组成的醒酒护肝的保健食品的配方及生产工艺 | |
CN103721074B (zh) | 一种药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |